Berenguer-Daizé, Caroline <br/><br/>
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.  [electronic resource] 

 -  International journal of cancer  11 2016 
 - 2047-55 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.30256  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetanilides--administration & dosage<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Blood-Brain Barrier--drug effects<br/>Brain Neoplasms--drug therapy<br/>Camptothecin--administration & dosage<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Dacarbazine--administration & dosage<br/>Drug Synergism<br/>Everolimus--administration & dosage<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Glioblastoma--drug therapy<br/>Heterocyclic Compounds, 3-Ring--administration & dosage<br/>Humans<br/>Irinotecan<br/>Mice<br/>Temozolomide<br/>Xenograft Model Antitumor Assays